Status:
UNKNOWN
Diabetic/Metabolic Cardiomyopathy: Prevalence and Phenotype
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Cardiopathy
Diabetes
Eligibility:
All Genders
Phase:
NA
Brief Summary
"Little is known about the prevalence, determinants and phenotypes of the cardiomyopathy associated with diabetes and/or metabolic syndrome. The emergence of new therapies (SGLT2 inhibitors) that may ...
Detailed Description
Heart failure (HF) is a frequent disease with a global prevalence of 2.3% that may culminate up to 10% in the elderly. HF is associated with poor outcomes, namely multiple recurrent hospitalizations a...
Eligibility Criteria
Inclusion
- Adults (18 years-old or more)
- At high metabolic risk: diabetes of any type and/or obesity (body mass index ≥ 30 kg/m²)
- Admission in the departement of Diabetology-Obesity-Nutrition, Avicenne Hospital, Bobigny, France
- Patient informed and having signed consent
- Patient affiliated to a social security scheme or entitled
Exclusion
- Any know cardiac disease: coronary artery disease, heart failure, cardiomyopathy, pulmonary embolism \< 6 months, pulmonary hypertension, rhythm disorders \< 6 months
- Blood pressure \> 180/110 mmHg
- Severe renal failure as defined by estimated glomerular filtration rate \< 30 ml/min
- Age ≥ 80 years
- Previous inclusion in the study
- Patient under guardianship curatorship
- Patient on AME (aide médicale d'état)
Key Trial Info
Start Date :
January 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 14 2023
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT05181631
Start Date
January 15 2022
End Date
September 14 2023
Last Update
January 6 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.